Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ena-DATASET-NU-14-08-2018-09:55:07:894-1179 - samples

ABSTRACT: Comprehensive genetic analyses including whole-exome sequencing, targeted sequencing, and whole-genome sequencing were performed to reveal the molecular pathogenesis of chronic active Epstein-Barr virus infection.

PROVIDER: EGAD00001004299 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

ena-DATASET-NU-14-08-2018-09:53:35:241-1178 - samples

Project description:Capture-based whole-genome sequencing of Epstein-Barr virus (EBV) was performed in hematological malignancies such as EBV-positive diffuse large B-cell lymphoma, extranodal NK/T-cell lymphoma, and chronic active EBV infection.

| EGAD00001004298 | EGA

ena-DATASET-NU-10-08-2018-06:36:49:104-536 - samples

Project description:Comprehensive genetic analyses including whole-exome sequencing, targeted sequencing, and whole-genome sequencing of the human genome and the Epstein-Barr virus (EBV) genome were performed to reveal the molecular pathogenesis of EBV-associated hematological malignancy.

| EGAD00001004286 | EGA

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

Project description:RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.

| 2005372 | ecrin-mdr-crc

Comprehensive genetic analysis of Epstein-Barr virus-associated hematological malignancy

| EGAS00001003159 | EGA

ena-DATASET-NU-14-08-2018-09:51:48:198-1177 - samples

Project description:Lymphoblastoid cell lines established using either wildtype or BALF5-deficient Epstein-Barr virus were analyzed by RNA sequencing.

| EGAD00001004297 | EGA

DNA methylation epigenotype expanding to non-polycomb target genes, induced by Epstein-Barr virus infection in human gastric cancer

Project description:This SuperSeries is composed of the following subset Series: GSE31787: Aberrant DNA methylation epigenotype expanding to non-polycomb target genes, induced by Epstein-Barr virus infection in human gastric cancer [Affymetrix Expression] GSE31788: Aberrant DNA methylation epigenotype expanding to non-polycomb target genes, induced by Epstein-Barr virus infection in human gastric cancer [Illumina Methylation] Refer to individual Series

2012-01-04 | E-GEOD-31789 | biostudies-arrayexpress

Peripheral blood gene expression in human experiencing primary EBV infection (Ref8)

Project description:Epstein Barr virus causes linfectious mononucleosis and establishes lifelong infection associated with cancer and autoimmune disease. To better understand immunity to EBV, we performed a prospective study of natural infection in healthy humans. These anlyses were undertaken in order to determine what gene expression changes occur as the result of primary Epstein Barr virus infection. Samples were taken both before and following acquisition of the virus for direct comparison of samples for single subjects. These data provide an important first description of the response to natural herepesvirus infection in humans. PBMC were taken before acquisition of EBV, during acute infection, and during latency

2013-12-31 | E-GEOD-45918 | biostudies-arrayexpress

Peripheral blood gene expression in human experiencing primary EBV infection (HT12)

2013-12-31 | E-GEOD-45919 | biostudies-arrayexpress

Peripheral blood gene expression in human experiencing primary EBV infection (HT12)

2013-12-31 | GSE45919 | GEO

Peripheral blood gene expression in human experiencing primary EBV infection (Ref8)

2013-12-31 | GSE45918 | GEO